Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.
This story was originally reported by CNBC. For the complete coverage and latest updates, visit the original source.
Read the full story at CNBC.
